1046832-21-6

Basic information

• Product Name: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester
• Synonyms: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester;1,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1,3-DiMethyl-1H-pyrazol-4-ylboronic acid,pinacol ester;1,3-Dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, 2-(1,3-Dimethyl-1H-pyrazol-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;1,3-DiMethylpyrazole-4-boronic acid pinacol ester;1,3-diMethyl-4-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyrazole;1,3-dimethyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole;1,3-Dimethylpyrazole-4-boronic acid pinacol ester 97%
• CAS NO: 1046832-21-6
• Molecular Formula: C₁₁H₁₉BN₂O₂
• Molecular Weight: 222.09
• Mol File: 1046832-21-6.mol

Chemical Properties

• Melting Point: 73.0 to 77.0 °C
• Boiling Point: 322.3±30.0 °C(Predicted)
• Appearance: /
• Density: 1.04±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.56±0.10(Predicted)
• CAS DataBase Reference: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester(1046832-21-6)
• EPA Substance Registry System: 1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester(1046832-21-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 1046832-21-6(Hazardous Substances Data)

Usage

Uses

1,3-Dimethyl-1H-pyrazole-4-boronic acid,pinacol ester

Upstream product

• 936250-20-3 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 74-88-4 methyl iodide 
• 5775-82-6 4-bromo-1,3-dimethyl-1H-pyrazole 
• 61676-62-8 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 73183-34-3 bis(pinacol)diborane 
• 694-48-4 1,3-dimethyl-1H-pyrazole 

Downstream Products

• 1616388-16-9 N-[1-(benzenesulfonyl)-2-(1,3-dimethylpyrazol-4-yl)pyrrolo[2,3-b]pyridin-5-yl]-4,5-dimethyl-1H-pyrazole-3-carboxamide 
• 1558007-83-2 5-(1,3-dimethyl-1H-pyrazol-4-yl)-3-{(1R)-1-[5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl]ethoxy}pyridin-2-amine 

Relevant articles and documents

Substituted heteroaryl compound and composition and application thereof

The invention provides a substituted heteroaryl compound and a pharmaceutical composition and application thereof. The compound is a compound as shown in formula (I) or the stereisomer, tautomer, nitric oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in formula (I). The pharmaceutical composition containing the compound can regulate the activity ofprotein kinase and especially the activity of Aurora kinase and JAK kinase and is used for preventing, treating and relieving diseases or disorder mediated by protein kinase and especially JAK kinase.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

NOVEL 4-(INDOL-3-YL)-PYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

The present invention embodiments relate to compound of Formula I or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates in certain embodiments to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates in certain embodiments to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates in certain embodiments to a process for manufacturing compounds of Formula I.

Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules

Compositions and methods which modulate diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including but not limited to cancer, inflammation, and bone related diseases.

CONDENSED TRICLYCLIC COMPOUNDS AS INHIBITORS OF HIV REPLICATION

Compounds of formula (I) and pharmaceutical compositions thereof: wherein A1 A2 and A3 are each independently selected from the group consisting of N and CR3, wherein R1 is an optionally substituted heterocyclyl or an optionally substituted -(C1-6)alkyl-heterocyclyl, R2 is an optionally substituted aryl or an optionally subsisted heteroaryl, R4 is an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inbitor of HIV replication.

CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.